Roche wins FDA approval for immunotherapy cocktail against lung cancer
Reuters: Health
Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.
Subscribe to:
Post Comments (Atom)
Subscribe UsPopular Posts
|
No comments:
Post a Comment